Syros Pharmaceuticals Inc. buy stratec
Summary
This prediction ended on 03.12.18 with a price of €68.82. The price of Syros Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -23.47%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | 1.702% | 1.702% | 73.188% | -88.832% |
| iShares Core DAX® | 3.178% | 0.980% | 15.331% | 18.044% |
| iShares Nasdaq 100 | 2.972% | 0.925% | 39.831% | 50.841% |
| iShares Nikkei 225® | 0.545% | -4.556% | 17.661% | 3.434% |
| iShares S&P 500 | 2.367% | 0.833% | 30.000% | 44.095% |
Comments by stratec for this prediction
In the thread Syros Pharmaceuticals Inc diskutieren
stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu
stratec stimmt am 08.01.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 28 $ zu.
Oppenheimer goes bullish on Syros Pharmaceuticals (SYRS) after they announced a research collaboration deal with Incyte (INCY). Oppenheimer's analyst assigns a buy rating and $28 price target on the stock. He had this to say about the deal:
Syros Pharmaceuticals and Incyte Corporation announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. Incyte will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets.
The companies reported the transaction is effective immediately.
Stopped prediction by stratec for Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc.
02.12.18
04.11.21
05.11.21
